Morphic Holding, Inc. (NASDAQ:MORF) insider Peter Linde sold 4,000 shares of the firm's stock in a transaction that occurred on Thursday, September 16th. The stock was sold at an average price of $66.51, for a total value of $266,040.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
NASDAQ:MORF traded up $0.71 on Friday, hitting $67.50. The stock had a trading volume of 972,918 shares, compared to its average volume of 277,714. The business's fifty day moving average is $60.35 and its 200 day moving average is $58.77. The company has a market cap of $2.46 billion, a PE ratio of -37.50 and a beta of 1.20. Morphic Holding, Inc. has a 52 week low of $24.52 and a 52 week high of $93.00.
Morphic (NASDAQ:MORF) last announced its quarterly earnings results on Wednesday, August 4th. The company reported ($0.77) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.22). The firm had revenue of $3.85 million during the quarter, compared to the consensus estimate of $5.80 million. Morphic had a negative return on equity of 24.79% and a negative net margin of 158.61%. The company's quarterly revenue was down 50.0% compared to the same quarter last year. As a group, analysts anticipate that Morphic Holding, Inc. will post -3.01 EPS for the current year.
Hedge funds have recently bought and sold shares of the company. Advisor Group Holdings Inc. bought a new position in shares of Morphic in the second quarter valued at approximately $57,000. Royal Bank of Canada lifted its holdings in shares of Morphic by 132.9% in the first quarter. Royal Bank of Canada now owns 1,125 shares of the company's stock valued at $71,000 after purchasing an additional 642 shares in the last quarter. FORA Capital LLC bought a new position in shares of Morphic in the first quarter valued at approximately $75,000. O Shaughnessy Asset Management LLC bought a new position in shares of Morphic in the first quarter valued at approximately $85,000. Finally, Ameritas Investment Partners Inc. lifted its holdings in shares of Morphic by 34.4% in the second quarter. Ameritas Investment Partners Inc. now owns 1,626 shares of the company's stock valued at $93,000 after purchasing an additional 416 shares in the last quarter. Institutional investors own 71.77% of the company's stock.
Separately, Zacks Investment Research cut Morphic from a "hold" rating to a "sell" rating in a research note on Friday, August 6th.
Morphic Holding, Inc operates as a biopharmaceutical company, which engages in the research and development of oral small-molecule integrin therapeutics. It operates a Morphic integrin technology platform, MInT platform, to create a broad pipeline of programs across a variety of therapeutic areas. The company was founded by Timothy A.
Featured Story: Basic Economics creates winners and losers
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Before you consider Morphic, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Morphic wasn't on the list.
While Morphic currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The 5 Stocks Here